As crisis deepens, Teva's board sees off CEO Erez Vigodman and an activist urges a split into two companies
The revolving door outside Teva’s executive suite is spinning again. A little more than three years after Jeremy Levin was unceremoniously pushed out of the CEO’s job, his successor is following in the same path, just days after back-to-back setbacks on sales projections and the loss of some key patents. And an activist investor says the latest signs of turmoil at Teva should spur a move to split the company between its generic operations and the branded group backed by a pipeline.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters